Dfn-15
HLA-A2 Positive Cells Present
Roswell Park Cancer InstitutePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 95/ 100
Competitive context
3 Active assets in the HLA-A2 Positive Cells Present cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
INTERFERON ALFA-2B Roswell Park Cancer Institute | Phase 2 | CCC |
Rintatolimod Roswell Park Cancer Institute | Phase 2 | CCC |
Alpha-Type-1 Polarized Dendritic Cells Roswell Park Cancer Institute | Phase 2 | C |
Same molecule, other indications
Dfn-15 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →